TAK-861, the drug that awakens patients with narcolepsy type 1

The existing treatments for type 1 narcolepsy are based on mitigating symptoms, with moderate success. Now, an international research in which Spanish centers have participated, published in the magazine 'The New England Journal of Medicine ', presents a new drug, TAK-86, which in a phase 2 clinical trial has shown its efficacy. Type 1 narcolepsy is a sleep disorder characterized by excessive daytime drowsiness, cataplegia, and other symptoms re…

Positive clinical results Next scientific day in Madrid The treatment of type 1 narcolepsy could be at the door of an important advance thanks to the results of an international study published today in the prestigious magazine New England Journal of Medicine. The research, in which 112 patients from different countries have participated, shows that TAK-861 (Oveporexton), a selective agonist of the orexin receptor 2, is highly effective in the c…

A drug to treat narcolepsy has shown “hoping” results by improving “significantly” the ability to stay awake, reduce daytime drowsiness and decrease the frequency of cataplegia episodes, according to a phase 2 clinical trial. Research with Spanish participation and published by the New England Journal of Medicine shows that TAK-861 (Oveporexton) is [...] The entry A drug to treat narcolepsy gives hopeful results in a phase 2 trial was first publ…

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated –Oveporexton Found to be Generally Safe and Well Tolerated –Phase 3 Readout of Oveporexton Anticipated in 2025 OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE: 4502/NYSE:TAK) today announced t…